(1-(Trifluoromethyl)cyclopropyl)methyl methanesulfonate, 250mg

2-(4-tert-Butyl-phenyl)-4,5-dimethyl-thiazole, 95.0%, 1g

DBD-NCS [=4-(N,N-Dimethylaminosulfonyl)-7-isothiocyanato-2,1,3-benzoxadiazole] [for HPLC Labeling and Edman Degradation]100mg

3,5-Dichloro-2-nitrobenzoic acid, 98%, 100mg

Colonne capillaire GC ROTI®Cap-1, 60 m, 0,32 mm, 0,50 µm, 1 pièce(s)

(E)-Ethyl 3-(pyrrolidin-1-yl)acrylate, 95.0%, 1g

3-Bromo-1-indanone, 97.0%, 1g

[4-Fluoro-3-(trifluoromethyl)phenyl](2,4,6-trimethoxyphenyl)iodonium p-Toluenesulfonate, >97.0%(HPLC), 1g

(R)-Methyl piperidine-3-carboxylate hydrochloride, 95.0%, 1g

Sodium 2-methylprop-2-ene-1-sulfonate, 95.0%, 1kg

7-BROMO-2-METHYL-3,4-DIHYDRO-2H-BENZO[B][1,4]OXAZINE, 97.0%, 250mg

1-(3-Chloro-4-methylphenyl)guanidine, 95.0%, 500mg

2-Bromo-6-chlorobenzamide, 250mg